<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629393</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1101-MCD-202</org_study_id>
    <nct_id>NCT02629393</nct_id>
  </id_info>
  <brief_title>Study of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A</brief_title>
  <official_title>A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of ALXN1101 in neonate patients with MoCD Type A
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response, defined as patients alive and able to sit upright independently for at least 30 seconds</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales of Infant Development® - Third Edition (Bayley - III®)</measure>
    <time_frame>First 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Evaluation of Disability Inventory (PEDI)</measure>
    <time_frame>First 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Molybdenum Cofactor Deficiency, Type A</condition>
  <arm_group>
    <arm_group_label>ALXN1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1101</intervention_name>
    <arm_group_label>ALXN1101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female neonatal patient (1 to 28 days of age [inclusive] at the time of
             ALXN1101 administration, with day 1 of age corresponding to the day of birth)

          -  Diagnosis of MoCD Type A, based on

          -  Prenatal genetic diagnosis, or

          -  Onset of clinical and/or laboratory signs and symptoms consistent with MoCD Type A
             (eg, seizures, exaggerated startle response, high-pitched cry, axial hypotonia, limb
             hypertonia, feeding difficulties, elevated urinary sulfite and/or SSC, elevated
             xanthine in urine or blood, or low or absent uric acid in the urine or blood) within
             the first 28 days after birth

          -  Parent or legal guardian must have signed the informed consent form (ICF) prior to any
             study procedures being performed

        Exclusion Criteria:

          -  Diagnosis other than MoCD Type A (may be determined after the initiation of study
             drug)

          -  Condition that is considered by the treating physician to be a contraindication to
             therapy, including evidence of abnormalities on brain imaging not attributable to MoCD
             Type A, or that might otherwise interfere with the patient's participation in the
             study, pose any additional risk for the patient, or confound patient assessments

          -  Antenatal and/or postnatal brain imaging prior to initiation of treatment with
             ALXN1101 that indicates cortical or subcortical cystic encephalomalacia, clinically
             significant intracranial hemorrhage, or other abnormalities on brain imaging
             determined by the treating physician to be clinically significant

          -  Modified Glasgow Coma Scale (mGCS) for Infants and Children score of less than 7 for
             more than 24 hours (This criterion does not apply to children less than 1 day in age).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital Femme Mère- Enfant</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18341</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willink Biochemical Genetics Unit</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molybdenum Cofactor Deficiency (MoCD)</keyword>
  <keyword>Molybdenum Cofactor (MoCo) biosynthesis</keyword>
  <keyword>sulfite oxidase (SO)</keyword>
  <keyword>S sulfocysteine (SSC)</keyword>
  <keyword>xanthine oxidoreductase</keyword>
  <keyword>aldehyde oxidase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

